MA43821A - Pyrimidines et variantes de celles-ci, et leurs utilisations - Google Patents
Pyrimidines et variantes de celles-ci, et leurs utilisationsInfo
- Publication number
- MA43821A MA43821A MA043821A MA43821A MA43821A MA 43821 A MA43821 A MA 43821A MA 043821 A MA043821 A MA 043821A MA 43821 A MA43821 A MA 43821A MA 43821 A MA43821 A MA 43821A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrimidins
- variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662308157P | 2016-03-14 | 2016-03-14 | |
US201662363630P | 2016-07-18 | 2016-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43821A true MA43821A (fr) | 2018-11-28 |
Family
ID=59850807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043821A MA43821A (fr) | 2016-03-14 | 2017-03-09 | Pyrimidines et variantes de celles-ci, et leurs utilisations |
Country Status (12)
Country | Link |
---|---|
US (1) | US10822311B2 (fr) |
EP (1) | EP3430000B1 (fr) |
JP (1) | JP6968810B2 (fr) |
KR (2) | KR102489454B1 (fr) |
CN (1) | CN108834412B (fr) |
AU (1) | AU2017233841B9 (fr) |
BR (1) | BR112018068399A2 (fr) |
CA (1) | CA3016773A1 (fr) |
MA (1) | MA43821A (fr) |
MX (1) | MX2018011136A (fr) |
RU (1) | RU2761439C2 (fr) |
WO (1) | WO2017160569A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3016773A1 (fr) | 2016-03-14 | 2017-09-21 | Ronald Charles Hawley | Pyrimidines et variantes de celles-ci, et leurs utilisations |
CA3018180C (fr) | 2016-03-25 | 2024-02-20 | Ronald Charles Hawley | Pyrimidines et variants de celles-ci, et leurs utilisations |
AU2017378785B2 (en) * | 2016-12-20 | 2021-07-29 | Afferent Pharmaceuticals, Inc. | Crystalline salts and polymorphs of a P2X3 antagonist |
AU2018246806B2 (en) | 2017-03-29 | 2022-05-12 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof |
CN107540699A (zh) * | 2017-10-16 | 2018-01-05 | 康化(上海)新药研发有限公司 | 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法 |
EP3846794A4 (fr) * | 2018-09-06 | 2022-06-22 | Monash University | Méthode de traitement d'un trouble respiratoire du sommeil |
CN113164490A (zh) * | 2018-10-10 | 2021-07-23 | 贝卢斯医疗咳嗽病公司 | 采用p2x3拮抗剂治疗瘙痒症 |
KR20200084802A (ko) | 2019-01-03 | 2020-07-13 | 주식회사 레고켐 바이오사이언스 | 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 |
US20220096641A1 (en) | 2019-01-03 | 2022-03-31 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer compound with improved safety and use thereof |
EP3960179A4 (fr) * | 2019-04-30 | 2023-01-25 | Beijing Tide Pharmaceutical Co., Ltd. | Méthode de traitement de la toux à l'aide d'un composé de diaminopyrimidine |
EP3964500A4 (fr) * | 2019-04-30 | 2022-12-21 | Beijing Tide Pharmaceutical Co., Ltd. | Sel d'un composé diaminopyrimidine, forme solide de celui-ci, procédé de préparation correspondant et utilisation associée |
BR112021021838A8 (pt) * | 2019-04-30 | 2023-02-28 | Beijing Tide Pharmaceutical Co Ltd | Método para tratar dor associada à endometriose com uso de composto de diaminopirimidina |
CA3138234A1 (fr) * | 2019-04-30 | 2020-11-05 | Beijing Tide Pharmaceutical Co., Ltd. | Forme solide de compose de diaminopyrimidine ou d'un hydrate de celui-ci, son procede de preparation et son application |
JP2022535852A (ja) * | 2019-06-06 | 2022-08-10 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | P2x3及び/又はp2x2/3受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
GB202006382D0 (en) | 2020-04-30 | 2020-06-17 | Spermatech As | Use |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2953567A (en) * | 1956-11-23 | 1960-09-20 | Burroughs Wellcome Co | 5-phenylmercaptopyrimidines and method |
EP1165522A1 (fr) * | 1999-04-06 | 2002-01-02 | Krenitsky Pharmaceuticals, Inc. | Thiopyrimidines neurotrophiques substitues |
BR0116411A (pt) | 2000-12-21 | 2003-11-11 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
EP2343282B1 (fr) * | 2004-03-05 | 2015-07-22 | F. Hoffmann-La Roche AG | Diaminopyrimidines en tant qu'antagonistes P2X3 et P2X2/3 |
JP4850913B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | P2x3及びp2x2/3調節因子としてのジアミノピリジン |
DK1924264T5 (en) * | 2005-09-01 | 2014-03-24 | Hoffmann La Roche | Diaminopyrimidines as P2X3- and P2X2 / 3 modulators |
CN101253159B (zh) * | 2005-09-01 | 2011-12-07 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物 |
JP4850911B2 (ja) | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | P2x3およびp2x2/3モジュレーターとしてのジアミノピリミジン |
WO2008104474A1 (fr) | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
WO2008104472A1 (fr) | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Dérivés de 2, 4 -diaminopyrimidine et utilisation de ces derniers comme antagonistes p2x ou comme promédicaments de ceux-ci |
JP5423679B2 (ja) * | 2007-10-31 | 2014-02-19 | 日産化学工業株式会社 | ピリダジノン化合物及びp2x7受容体阻害剤 |
GB2471713A (en) | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
EP2467142B1 (fr) * | 2009-08-17 | 2016-09-21 | Memorial Sloan-Kettering Cancer Center | Dérivés 2-(pyrimidin-5-yl)-thiopyrimidine en tant que modulateurs Hsp70 and Hsc70 pour le traitement de maladies proliferatives |
TWI637949B (zh) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
CA3016773A1 (fr) | 2016-03-14 | 2017-09-21 | Ronald Charles Hawley | Pyrimidines et variantes de celles-ci, et leurs utilisations |
CA3018180C (fr) | 2016-03-25 | 2024-02-20 | Ronald Charles Hawley | Pyrimidines et variants de celles-ci, et leurs utilisations |
-
2017
- 2017-03-09 CA CA3016773A patent/CA3016773A1/fr active Pending
- 2017-03-09 AU AU2017233841A patent/AU2017233841B9/en active Active
- 2017-03-09 JP JP2018548184A patent/JP6968810B2/ja active Active
- 2017-03-09 EP EP17767179.9A patent/EP3430000B1/fr active Active
- 2017-03-09 US US16/077,904 patent/US10822311B2/en active Active
- 2017-03-09 KR KR1020217038082A patent/KR102489454B1/ko active IP Right Grant
- 2017-03-09 CN CN201780016980.6A patent/CN108834412B/zh active Active
- 2017-03-09 BR BR112018068399A patent/BR112018068399A2/pt active Search and Examination
- 2017-03-09 MA MA043821A patent/MA43821A/fr unknown
- 2017-03-09 RU RU2018134945A patent/RU2761439C2/ru active
- 2017-03-09 MX MX2018011136A patent/MX2018011136A/es unknown
- 2017-03-09 WO PCT/US2017/021477 patent/WO2017160569A1/fr active Application Filing
- 2017-03-09 KR KR1020187029170A patent/KR20180122406A/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
MX2018011136A (es) | 2019-01-14 |
CA3016773A1 (fr) | 2017-09-21 |
JP2019508445A (ja) | 2019-03-28 |
RU2018134945A (ru) | 2020-04-15 |
RU2018134945A3 (fr) | 2020-05-19 |
EP3430000B1 (fr) | 2022-12-28 |
CN108834412A (zh) | 2018-11-16 |
WO2017160569A1 (fr) | 2017-09-21 |
KR102489454B1 (ko) | 2023-01-17 |
KR20180122406A (ko) | 2018-11-12 |
AU2017233841A1 (en) | 2018-09-06 |
EP3430000A4 (fr) | 2019-12-04 |
AU2017233841B9 (en) | 2021-09-09 |
EP3430000A1 (fr) | 2019-01-23 |
BR112018068399A2 (pt) | 2019-01-15 |
KR20210144941A (ko) | 2021-11-30 |
RU2761439C2 (ru) | 2021-12-08 |
CN108834412B (zh) | 2022-11-25 |
US10822311B2 (en) | 2020-11-03 |
AU2017233841B2 (en) | 2021-09-02 |
JP6968810B2 (ja) | 2021-11-17 |
US20190389811A1 (en) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA44489A (fr) | Pyrimidines et variants de celles-ci, et leurs utilisations | |
MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
MA53400A (fr) | Hétéromultimères alk7: actriib et leurs utilisations | |
MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA41598A (fr) | Composés thérapeutiques de pyridazine et leurs utilisations | |
MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
MA44986A (fr) | Protéines de fusion gdf15 et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
MA55044A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
MA43529A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
MA43205A (fr) | Composés pyy sélectifs et leurs utilisations | |
MA43567A (fr) | Anticorps pacap et leurs utilisations | |
MA45943A (fr) | Compositions ignifuges et leurs utilisations | |
MA46472A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
MA46700A (fr) | Variants polypeptidiques et ses utilisations | |
MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA45233A (fr) | Anticorps anti-gitr et leurs utilisations |